The clinical role of genetic polymorphisms in drug-metabolizing enzymes.
about
Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancerCYP2C19 polymorphism influences Helicobacter pylori eradicationGene expression variability in human hepatic drug metabolizing enzymes and transportersAccessing and integrating data and knowledge for biomedical research.Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample.Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy.Residual effects of esmirtazapine on actual driving performance: overall findings and an exploratory analysis into the role of CYP2D6 phenotypePolymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatmentEffects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials.Clinically significant psychotropic drug-drug interactions in the primary care setting.Pharmacogenomics of antidepressant treatment effectsLooking to the future: incorporating genomic information into disparities research to reduce measurement error and selection bias.Studying copy number variations using a nanofluidic platform.Genelex Corporation.Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy.Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans.The role of pharmacogenetics and pharmacogenomics in improving translational medicine.Implementation of CYP2D6 genotyping in psychiatry.Genetic polymorphisms of metabolic enzymes and the pharmacokinetics of indapamide in Taiwanese subjectsDo we need pharmacogenetics to personalize antidepressant therapy?Integrating cardiomyocytes from human pluripotent stem cells in safety pharmacology: has the time come?Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvementThe 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugsEffects of EPHX1 and CYP3A4 polymorphisms on carbamazepine metabolism in epileptic patients.Pharmacogenetics aspects of oral anticoagulants therapy.Desipramine Increases Genioglossus Activity and Reduces Upper Airway Collapsibility during Non-REM Sleep in Healthy SubjectsIn vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substratesA computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks.A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail.Identification of genetic variants of human cytochrome P450 2D6 with impaired mitochondrial targeting.Functional diversity of the glutathione peroxidase gene family among human populations: implications for genetic predisposition to disease and drug response.A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD).CYP2D6*3, *4, *5 AND *6 POLYMORPHISMS AND ANTIPSYCHOTIC-INDUCED EXTRAPYRAMIDAL SIDE-EFFECTS IN PATIENTS RECEIVING ANTIPSYCHOTIC THERAPY
P2860
Q24642847-D1A73B6E-D707-4192-88C5-BF0811E1A661Q27005916-B5188D5D-6438-4686-8734-786A04D0281FQ28486732-AC3AD9F7-4677-4347-A264-950287AE0CC3Q31165447-726249C2-A6EA-4F03-8BED-FCE378D38446Q33326612-EAB67803-BC08-4F06-9D30-F2AD86AC8A5DQ33664128-D859EC7A-39C5-4011-ABE6-C52ACD0CB434Q33796782-B0EDAC99-0FB1-4A04-B30B-37D6E3BCA6BCQ34661625-0A64311B-C2E9-4DAB-AB47-0F342BF823D5Q34706721-E9C987BA-8A9D-45BA-8954-CED6FD746CB8Q35104220-B088AD82-6E5B-4DB0-9B38-459FAB59C47BQ35237236-BB10385C-E295-4B25-8E8F-72917316CAC2Q36163437-62C9D929-DB54-4CE8-AD8F-C5637046DA89Q36935421-97BEC434-1849-4278-95B2-DDCFAAF9BEABQ37126673-8B8BE11F-815A-45C6-8BA8-76AE4C39B2E8Q37278622-64828E03-FEF1-48A8-9C36-6DA50320B45CQ37363157-3DFC3202-051C-4947-9E01-58F47C9330BDQ37430412-AFA77231-5DF7-49E9-A8A2-87A3722C3172Q37538787-94538E69-9122-4CD2-ADD0-0444DB7245C7Q37601055-EDE1B39A-1FE1-45D7-B554-8BF24047AB74Q38070163-1DA50CE2-D7D2-4AEE-A749-19599DD181D1Q38819976-BF2FA5C5-46CF-44DC-896F-1632E3ADC963Q38842969-1653BFD0-CB8C-4327-BFBF-F1F3F07E8A5CQ39102558-A7DB0873-C257-4A84-B134-FE5F4966FBC7Q39313577-780C5CC8-4A2C-430B-9C8B-26D24AB9FB2FQ39469904-84095EB8-FF08-41A9-9E6F-2EDD22137A6FQ39928691-2885328E-7EFA-4063-9E5B-3B255F4330A4Q41986948-537B56D4-E2DF-43D5-B4A9-95C8C10EE3CBQ42018625-A73D5D38-4FCA-4DE6-988F-339C34B426C6Q42282507-09FD7E97-AED4-4DD4-94D9-BEEF1F2EE5EBQ42951784-EE213649-1991-42EB-99F8-FA174417EF6FQ44297212-66A93D01-E67A-44DF-B1CD-D82D9BC03FA5Q46040109-C49E32F2-D733-49B9-B1E2-7857AB97FF8FQ57602700-90A517F6-0E2C-4CA2-86A2-08C1E016AF51
P2860
The clinical role of genetic polymorphisms in drug-metabolizing enzymes.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The clinical role of genetic polymorphisms in drug-metabolizing enzymes.
@en
type
label
The clinical role of genetic polymorphisms in drug-metabolizing enzymes.
@en
prefLabel
The clinical role of genetic polymorphisms in drug-metabolizing enzymes.
@en
P2093
P2860
P356
P1476
The clinical role of genetic polymorphisms in drug-metabolizing enzymes.
@en
P2093
Kirchheiner J
Tomalik-Scharte D
P2860
P2888
P356
10.1038/SJ.TPJ.6500462
P577
2007-06-05T00:00:00Z